Citi analyst David Lebowitz raised the firm’s price target on Alnylam Pharmaceuticals to $266 from $265 and keeps a Buy rating on the shares. The company reported a Q2 net product revenue beat, driven by strong Amvuttra sales, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALNY: